“✓”: guideline explicitly mentions evidence or outcome. Empty cell: guideline does not explicitly mention evidence or outcome. ^#: qualitatively considered. ^¶: composite end-point of need for IMV or death. ⁺: includes guidelines which only provided recommendations against casirivimab/imdevimab or recommended against casirivimab/imdevimab for at least one disease severity category and reported insufficient evidence for any other categories. Organisations: AWMF: Association of the Scientific Medical Societies in Germany; CIDS: Clinical Infectious Disease Society; MoH: Ministry of Health; NICE: National Institute for Health and Care Excellence; NIH: National Institutes of Health; SIP: Italian Society of Pulmonology; SITA: Italian Society of Anti-Infective Therapy; WHO: World Health Organization. Abbreviations: ICU: intensive care unit; IMV: invasive mechanical ventilation; NCT: National Clinical Trial; RCT: randomised controlled trial. Other outcomes considered: ^a: admission to hospital; time to symptom improvement. ^b: time-weighted average daily change from baseline viral load in nasopharyngeal samples from day 1–7. ^c: need for dialysis; neurological function; viral clearance. ^d: progression to noninvasive ventilation; progression to organ replacement therapy. ^e: within 28 days of randomisation: noninvasive mechanical ventilation. ^f: reduction in hospitalisations. Sources: AWMF, October 2021 [24]; CIDS, August 2021 [29]; COVID-19 Advisory Ontario, November 2021 [31]; Government of Mexico, August 2021 [35]; IDSA, October 2021 [36]; J-SSCG, September 2021 [37]; MoH Brazil, May 2021 [38]; NICE, January 2022 [8]; NIH, December 2021 [39]; SITA/SIP, May 2021 [40]; WHO, January 2022 [9].